阿加曲班联合依达拉奉治疗进展性脑梗死临床分析

Clinical Observation of Argatroban Combining Edarovone Treating Progressive Cerebral Infarction-A Report of 38 Cases

目的观察阿加曲班(Argatroban)联合依达拉奉(Edarovone)治疗进展性脑梗死的临床疗效并探讨其可能的作用机制。方法将114例进展性脑梗死患者随机分为A、B、C组,每组各38例。3组均给予改善循环、抗血小板聚集等常规治疗,在此基础上A组给予阿加曲班、依达拉奉静滴;B组静滴依达拉奉,方法、剂量同上;C组予血栓通静滴。3组在治疗开始、治疗后进行临床神经功能缺损程度(CSS)评分与日常生活活动能力量表(BI)评分。结果在治疗A、B组显效率均显著高于C组(P<0.05);治疗后症状评分均显著低于治疗前及C组,A组低于B组。结论阿加曲班联合依达拉奉对进展性脑梗死有较好治疗效果。

Objective To observe the clinical effects of Argatroban combining Edarovone treating progressive cerebral infarction and its mechanism of function.Methods One hundred and fourteen cases with progressive cerebral infarction were randomized into three groups,group A（n=38）,group B（n=38） and group C（n=38）.All the three groups received routine treatment for circulation improvement and anti-platelet aggregation.In addition,group A received argatroban combining edarovone intravenously,group B received edarovone with the method and dosage as group A.Group C received Sanqi Panax Notoginseng intravenously.All the patients were assessed with CSS and BI before and after treatment.Results The significant efficiency in group A and group B was higher than that in group C（P0.05）.The symptom scores in group A and group B were significantly decreased and lower than group C with group A lower than group B.Conclusion Argatroban combining Edarovone treating progressive cerebral infarction could show good therapeutic effects.